The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in The BMJ.
These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells.